Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 158-162

  Phippen, Neil T ^a   Barnett, Jason C ^a   Lowery, William J ^a,b   Miller, Caela R ^a   Leath III, Charles A ^a,c  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cancer care disparities; Centralization of care; Epithelial ovarian cancer; NCCN guidelines; Surgical cytoreduction

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; COHORT ANALYSIS; COLON RESECTION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM INJURY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MULTIMODALITY CANCER THERAPY; NEUROLOGIC DISEASE; OMENTECTOMY; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT COMPLIANCE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SMALL INTESTINE RESECTION; SPLENECTOMY; SURGICAL APPROACH; SURGICAL MORTALITY; THROMBOCYTE TRANSFUSION; URINARY TRACT INFECTION; UTERINE TUBE CARCINOMA;

EID: 84885299083     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.001     Document Type: Article

References (15)

1. Siegel R, NaishadhamD, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1): 10-29.
2. Bristow RE, et al. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 2013;105(11): 823-32.
3. NCCN. Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer). 28 Nov 2011 01 Aug 2012]; Version 2.2012:[Available from: http://www. nccn.org.
4. Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol 2010;118(3): 262-7.
5. Chi DS, et al.What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103(2): 559-64.
6. Winter IIIWE, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2008;26(1): 83-9.
7. Hamilton CA, et al. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol 2011;122(3): 521-6.
8. Aletti GD, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107(1): 77-85.
9. Winter III WE, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25(24): 3621-7.
10. Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. Gynecol Oncol 2012;125(2): 483-92.
11. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47(2): 159-66.
12. Wright JD, et al. Failure to rescue as a source of variation in hospital mortality for ovarian cancer. J Clin Oncol 2012;30(32): 3976-82.
13. Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? Gynecol Oncol 2013;128(1): 6-11.
14. Vergote I, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10): 943-53.
15. Chi DS, Bristow RE, Armstrong DK, Karlan BY. Is the easier way ever the better way? J Clin Oncol 2011;29(31): 4073-5.